Mene Pangalos (AstraZeneca via YouTube)

As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

When Io­n­is and As­traZeneca un­veiled the first round of mid-stage da­ta for their an­ti­sense PC­SK9 drug, Mene Pan­ga­los, As­traZeneca’s EVP of bio­phar­ma­ceu­ti­cals R&D, un­der­scored the drug’s “po­ten­tial best-in-class ef­fi­ca­cy pro­file.”

But now that the sec­ond batch is in, it ap­pears AZD8233 isn’t hit­ting the mark af­ter all.

Io­n­is an­nounced Fri­day morn­ing that al­though the can­di­date, al­so dubbed ION449, met the pri­ma­ry end­point in the Phase IIb SOLANO tri­al, its part­ners at As­traZeneca have de­cid­ed not to move it in­to Phase III stud­ies be­cause the “re­sults did not achieve pre-spec­i­fied ef­fi­ca­cy cri­te­ria.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.